Skip to main content
Erschienen in: Journal of Gastroenterology 12/2020

26.08.2020 | Original Article—Liver, Pancreas, and Biliary Tract

Durable response without recurrence to Tolvaptan improves long-term survival

verfasst von: Masato Nakai, Goki Suda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto

Erschienen in: Journal of Gastroenterology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Decompensated liver cirrhosis patients with refractory ascites or pleural effusion have a poor prognosis. Tolvaptan has been used for treating water retention associated with cirrhosis. However, despite the short-term response, water retention recurrence is still observed in some cases. This study aimed to clarify the water retention recurrence rate and the relationship between long-term response without recurrence and prognosis.

Methods

Altogether, 100 patients with decompensated cirrhosis treated with tolvaptan were retrospectively analyzed. Recurrence was evaluated according to the criteria of the EASL clinical practice guideline. The recurrence rate and prognosis of non-responders, patients with recurrence, and long-term responders were analyzed. The baseline factors related to short-term response, recurrence, and long-term response were also evaluated.

Results

Approximately 31.0% of the short-term responders had recurrence. Although there was no significant difference in the prognosis by short-term response (p = 0.07), the long-term responders had a significantly better prognosis than those with recurrence and non-responders (p < 0.01). Low CRP levels and high urinary Na/K ratios were significant factors related to short-term response, and the presence of acute kidney injury was also a factor related to non-response. The low CRP level (relapse: < 1.10 mg/dl, long-term response: < 0.94 mg/dl) was identified as a factor related to recurrence and long-term response.

Conclusion

The long-term responders without recurrence had a significantly better prognosis. CRP was a useful predictor for long-term response, whereas renal function parameters were useful predictors for short-term response. Inflammation control may be important for long-term response and prognosis in cirrhosis patients with water retention.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–94.PubMed Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–94.PubMed
2.
Zurück zum Zitat Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites results of a randomized study. Gastroenterology. 1987;93:234–41.PubMed Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites results of a randomized study. Gastroenterology. 1987;93:234–41.PubMed
3.
Zurück zum Zitat Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131–7.PubMed Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131–7.PubMed
4.
Zurück zum Zitat Mandai S, Furukawa S, Kodaka M, et al. Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Sci Rep. 2017;7:46369.PubMedPubMedCentral Mandai S, Furukawa S, Kodaka M, et al. Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Sci Rep. 2017;7:46369.PubMedPubMedCentral
5.
Zurück zum Zitat Hanai T, Shiraki M, Miwa T, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatol Res. 2019;49:82–95.PubMed Hanai T, Shiraki M, Miwa T, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatol Res. 2019;49:82–95.PubMed
6.
Zurück zum Zitat Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(166–73):73.e1. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(166–73):73.e1.
7.
Zurück zum Zitat Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.PubMed Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.PubMed
8.
Zurück zum Zitat Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73–82.PubMed Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73–82.PubMed
9.
Zurück zum Zitat Sakaida I, Terai S, Kurosaki M, et al. Effectiveness and safety of Tolvaptan in liver cirrhosis patients with edema: interim results of post-marketing surveillance of Tolvaptan in liver cirrhosis (START study). Hepatol Res. 2017;47:1137–46.PubMed Sakaida I, Terai S, Kurosaki M, et al. Effectiveness and safety of Tolvaptan in liver cirrhosis patients with edema: interim results of post-marketing surveillance of Tolvaptan in liver cirrhosis (START study). Hepatol Res. 2017;47:1137–46.PubMed
11.
Zurück zum Zitat Ohki T, Sato K, Yamada T, et al. Efficacy of Tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015;7:1685–93.PubMedPubMedCentral Ohki T, Sato K, Yamada T, et al. Efficacy of Tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015;7:1685–93.PubMedPubMedCentral
12.
Zurück zum Zitat Chishina H, Hagiwara S, Nishida N, et al. Clinical factors predicting the effect of Tolvaptan for refractory ascites in patients with decompensated liver cirrhosis. Dig Dis. 2016;34:659–64.PubMed Chishina H, Hagiwara S, Nishida N, et al. Clinical factors predicting the effect of Tolvaptan for refractory ascites in patients with decompensated liver cirrhosis. Dig Dis. 2016;34:659–64.PubMed
13.
Zurück zum Zitat Iwamoto T, Maeda M, Hisanaga T, et al. Predictors of the effect of Tolvaptan on the prognosis of cirrhosis. Intern Med. 2016;55:2911–6.PubMedPubMedCentral Iwamoto T, Maeda M, Hisanaga T, et al. Predictors of the effect of Tolvaptan on the prognosis of cirrhosis. Intern Med. 2016;55:2911–6.PubMedPubMedCentral
14.
Zurück zum Zitat Nakagawa A, Atsukawa M, Tsubota A, et al. Usefulness of portal vein pressure for predicting the effects of Tolvaptan in cirrhotic patients. World J Gastroenterol. 2016;22:5104–13.PubMedPubMedCentral Nakagawa A, Atsukawa M, Tsubota A, et al. Usefulness of portal vein pressure for predicting the effects of Tolvaptan in cirrhotic patients. World J Gastroenterol. 2016;22:5104–13.PubMedPubMedCentral
15.
Zurück zum Zitat Yamada T, Ohki T, Hayata Y, et al. Potential effectiveness of Tolvaptan to improve ascites unresponsive to standard diuretics and overall survival in patients with decompensated liver cirrhosis. Clin Drug Investig. 2016;36:829–35.PubMed Yamada T, Ohki T, Hayata Y, et al. Potential effectiveness of Tolvaptan to improve ascites unresponsive to standard diuretics and overall survival in patients with decompensated liver cirrhosis. Clin Drug Investig. 2016;36:829–35.PubMed
16.
Zurück zum Zitat Hiramine Y, Uto H, Imamura Y, et al. Efficacy of vasopressin V2 receptor antagonist Tolvaptan in treatment of hepatic edema. Hepatol Res. 2017;47:542–57.PubMed Hiramine Y, Uto H, Imamura Y, et al. Efficacy of vasopressin V2 receptor antagonist Tolvaptan in treatment of hepatic edema. Hepatol Res. 2017;47:542–57.PubMed
17.
Zurück zum Zitat Kawaratani H, Fukui H, Moriya K, et al. Predictive parameter of Tolvaptan effectiveness in cirrhotic ascites. Hepatol Res. 2017;47:854–61.PubMed Kawaratani H, Fukui H, Moriya K, et al. Predictive parameter of Tolvaptan effectiveness in cirrhotic ascites. Hepatol Res. 2017;47:854–61.PubMed
18.
Zurück zum Zitat Komiyama Y, Kurosaki M, Nakanishi H, et al. Prediction of diuretic response to Tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS ONE. 2017;12:e0174649.PubMedPubMedCentral Komiyama Y, Kurosaki M, Nakanishi H, et al. Prediction of diuretic response to Tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS ONE. 2017;12:e0174649.PubMedPubMedCentral
19.
Zurück zum Zitat Uojima H, Kinbara T, Hidaka H, et al. Close correlation between urinary sodium excretion and response to Tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2017;47:E14–e21.PubMed Uojima H, Kinbara T, Hidaka H, et al. Close correlation between urinary sodium excretion and response to Tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2017;47:E14–e21.PubMed
20.
Zurück zum Zitat Atsukawa M, Tsubota A, Kato K, et al. Analysis of factors predicting the response to Tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol. 2018;33:1256–63.PubMed Atsukawa M, Tsubota A, Kato K, et al. Analysis of factors predicting the response to Tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol. 2018;33:1256–63.PubMed
21.
Zurück zum Zitat Hayashi M, Abe K, Fujita M, et al. Association between the serum sodium levels and the response to Tolvaptan in liver cirrhosis patients with ascites and hyponatremia. Intern Med. 2018;57:2451–8.PubMedPubMedCentral Hayashi M, Abe K, Fujita M, et al. Association between the serum sodium levels and the response to Tolvaptan in liver cirrhosis patients with ascites and hyponatremia. Intern Med. 2018;57:2451–8.PubMedPubMedCentral
22.
Zurück zum Zitat Nakai M, Ogawa K, Takeda R, et al. Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of Tolvaptan in patients with liver cirrhosis. Hepatol Res. 2018;48:E311–E319319.PubMed Nakai M, Ogawa K, Takeda R, et al. Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of Tolvaptan in patients with liver cirrhosis. Hepatol Res. 2018;48:E311–E319319.PubMed
23.
Zurück zum Zitat Arase Y, Kagawa T, Tsuruya K, et al. impaired renal function may not negate the efficacy of Tolvaptan in the treatment of cirrhotic patients with refractory ascites. Clin Drug Investig. 2019;39:45–544.PubMed Arase Y, Kagawa T, Tsuruya K, et al. impaired renal function may not negate the efficacy of Tolvaptan in the treatment of cirrhotic patients with refractory ascites. Clin Drug Investig. 2019;39:45–544.PubMed
24.
Zurück zum Zitat Kida Y. Positive response to Tolvaptan treatment would be a good prognostic factor for cirrhotic patients with ascites. Dig Dis. 2019;37:239–46.PubMed Kida Y. Positive response to Tolvaptan treatment would be a good prognostic factor for cirrhotic patients with ascites. Dig Dis. 2019;37:239–46.PubMed
25.
Zurück zum Zitat Sagawa E, Okubo H, Ando H, et al. Plasma concentration and efficacy of Tolvaptan in cirrhotic patients with refractory ascites. J Pharmacol Sci. 2019;139:373–6.PubMed Sagawa E, Okubo H, Ando H, et al. Plasma concentration and efficacy of Tolvaptan in cirrhotic patients with refractory ascites. J Pharmacol Sci. 2019;139:373–6.PubMed
26.
Zurück zum Zitat Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of Tolvaptan for the treatment of hepatic edema. J Gastroenterol. 2018;53:258–68.PubMed Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of Tolvaptan for the treatment of hepatic edema. J Gastroenterol. 2018;53:258–68.PubMed
27.
Zurück zum Zitat Bellos I, Kontzoglou K, Perrea DN. Predictors of Tolvaptan short-term response in patients with refractory ascites: a meta-analysis. J Gastroenterol Hepatol. 2020;35:182–91.PubMed Bellos I, Kontzoglou K, Perrea DN. Predictors of Tolvaptan short-term response in patients with refractory ascites: a meta-analysis. J Gastroenterol Hepatol. 2020;35:182–91.PubMed
28.
Zurück zum Zitat European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60.
30.
Zurück zum Zitat Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Int Ascites Club J Hepatol. 2000;32:142–53. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Int Ascites Club J Hepatol. 2000;32:142–53.
31.
Zurück zum Zitat Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–74.PubMed Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–74.PubMed
32.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.PubMed Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.PubMed
33.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMed Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMed
34.
Zurück zum Zitat Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.PubMed Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.PubMed
35.
Zurück zum Zitat Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805.PubMed Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805.PubMed
36.
Zurück zum Zitat Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–c184184.PubMed Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–c184184.PubMed
37.
Zurück zum Zitat Maatman RG, van de Westerlo EM, van Kuppevelt TH, et al. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J. 1992;288:285–90.PubMedPubMedCentral Maatman RG, van de Westerlo EM, van Kuppevelt TH, et al. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J. 1992;288:285–90.PubMedPubMedCentral
38.
Zurück zum Zitat Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175–82.PubMed Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175–82.PubMed
39.
Zurück zum Zitat Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008;73:465–72.PubMed Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008;73:465–72.PubMed
40.
Zurück zum Zitat Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006;47:439–44.PubMed Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006;47:439–44.PubMed
41.
Zurück zum Zitat Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol. 2014;9:1857–67.PubMedPubMedCentral Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol. 2014;9:1857–67.PubMedPubMedCentral
42.
Zurück zum Zitat Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60:622–32.PubMed Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60:622–32.PubMed
43.
Zurück zum Zitat Hiramine Y, Uto H, Mawatari S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res. 2019;49:765–77.PubMed Hiramine Y, Uto H, Mawatari S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res. 2019;49:765–77.PubMed
44.
Zurück zum Zitat Iwamoto T, Maeda M, Saeki I, et al. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites. J Gastroenterol Hepatol. 2019;34:1231–5.PubMed Iwamoto T, Maeda M, Saeki I, et al. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites. J Gastroenterol Hepatol. 2019;34:1231–5.PubMed
Metadaten
Titel
Durable response without recurrence to Tolvaptan improves long-term survival
verfasst von
Masato Nakai
Goki Suda
Akinori Kubo
Yoshimasa Tokuchi
Takashi Kitagataya
Ren Yamada
Taku Shigesawa
Kazuharu Suzuki
Akihisa Nakamura
Naoki Kawagishi
Masatsugu Ohara
Machiko Umemura
Takuya Sho
Kenichi Morikawa
Koji Ogawa
Naoya Sakamoto
Publikationsdatum
26.08.2020
Verlag
Springer Singapore
Erschienen in
Journal of Gastroenterology / Ausgabe 12/2020
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01721-8

Weitere Artikel der Ausgabe 12/2020

Journal of Gastroenterology 12/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.